An observational study in Cardiac Failure, sponsored by Wang . Jiun-Jie. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Wang . Jiun-Jie · Observational
In recent years, evaluating cardiac function with magnetic resonance imaging (MRI) has drawn widespread interest. However, cardiac MRI is prone to severe motion artifacts from cardiac contraction, frequently requiring complex triggering procedures to enhance image quality-a task that typically demands a highly skilled technologist to execute within limited clinical time. As there is currently no optimized cardiac MRI protocol at Chang Gung Memorial Hospital, this subproject aims to first establish a clinically feasible, optimized protocol to support other subprojects and future studies. The investigators will develop a standard operating procedure (SOP) and subsequently use it to evaluate recovery in heart failure patients.
Over this three-year project, the investigators plan to use MRI to evaluate cardiac morphology and function in heart failure patients. In Year 1, the investigators will establish a clinically feasible protocol to assess myocardial stability; baseline images from healthy controls will be incorporated into the integrated project. In Year 2, the investigators will introduce accelerated imaging techniques, assess the correlation between disease severity and MRI findings, and measure cardiac diffusion parameters. In Year 3, the investigators will follow heart failure patients to monitor their recovery process.
Patients with myocardial diseases might suffer from a serious impact on daily living activity, which could lead to increased care burden. Because of the very low capacity in myocardial regeneration, tissue damage by myocardial necrosis is usually irreversible. Therefore, great interest has been raised to monitor the healthy myocardial conditions, to prevent the occurrence and the subsequent deterioration of the myocardial disease, preferably with non-invasive methods. Computed tomography (CT), ultrasound, and magnetic resonance image (MRI) were widely used as image-based diagnostic techniques without invasive for myocardial tissue. In this regard, although CT could provide superior spatial resolution, its performance at discriminating between soft-tissue lesions of cardiomyopathy might be less than satisfactory. The limited temporal resolution, the risk from radiation, and the use of contrast agent might raise further concerns. Cardiac MRI (CMRI) might provide a choice because of the improved contrast and the non-invasive nature without the need to use a contrast agent.
The myocardial T1 and T2∗ relaxation time, as derived from CMRI, have been previously reported in many cardiomyopathies such as acute myocardial infarction, fibrosis, and iron deposition. For diagnosis, quantitative values of relaxation time were often obtained from either healthy myocardial tissue, such as the remotely-located unaffected tissue from the same participant, or healthy volunteers. These quantitative maps provide an objective assessment of the myocardial tissue properties in comparison to the disease-induced abnormalities or diffused changes within myocardium.
The Caucasian population usually has a high cardiovascular-disease-related mortality rate. In contrast, the Asian population has a higher mortality rate by stroke, which was often attributed to the poor control of cardiovascular risk factors, such as high blood pressure or cholesterol level. The relaxation time in the healthy myocardium was previously reported from the Caucasian population. To evaluate the potential relationship between clinical parameters and quantitative mapping from CMRI, mastered the reference values of T1 and T2∗ relaxation time of myocardium in healthy populations were important. This study aimed to measure and report the T1 and T2∗ relaxation time of myocardium in healthy Taiwanese participants. The investigators further investigated the association between T1, T2∗ relaxation time of myocardium, and clinical parameters, including blood pressure, pulses rate, and ejection fraction.
5,801 studies on the registry are indexed under Heart Failure; 1,222 are open to participants now.
This study's enrollment of 120 is below the median of 200 across 1,719 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Wang . Jiun-Jie is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The healthy control will be recruited from the local community in northern Taiwan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Heart Failure Group: 30 subjects
Healthy Controls: subjects = 30 (20 in the first year and 10 in the second year, cross-sectional)
Healthy Controls for optimization: subjects = 60 (20 in each year, for protocol optimization )
Exclusion Criteria:
The following exclusion criteria apply to all groups.
* Aged between 20 and 70 year old. * Able to understand and provide signed informed consent. * Without documented cardiac disorder. * Age and gender matched the heart failure group
* Aged between 20 and 70 year old. * Able to understand and provide signed informed consent * without documented cardiac disorder * Age and gender matched the heart failure group
* All participants should be aged between 20 and 70 year old. * Established diagnosis by a cardiological examination. * Able to understand and provide signed informed consent. * Patients must be willing to undergo standard treatment and follow up in the Heart Failure Center.
MRI acquisition
73 normal participants assesed by MRI
Time frame: 3 years
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wang . Jiun-Jie